$COAG
Hemab Therapeutics Holdings, Inc. Common Stock
XNAS•Health Care•Biological Products, (No Diagnostic Substances)
$41.19
▼-0.07%-$0.030
Subscriptions are live. Early access $24.99/mo, or start with 5 free premium days.
Plans & pricingDonateHemab Therapeutics Holdings, Inc. Common Stock
XNAS•Health Care•Biological Products, (No Diagnostic Substances)
Why is COAG down today? It is at $41.19 (-0.07%), and our scanner flagged it 58 times on unusual volume this month. See the catalyst behind the move, real-time alerts the moment COAG spikes, and full due diligence on COAG — key stats, earnings, dilution and insider activity. Free.
Our scanner flagged $COAG 58 times in the last 30 days. Create a free account to track $COAG, build a watchlist, and get instant unusual-volume alerts, with a full day of premium now and 5 more when you verify your email, no card needed.
No card · 5 premium days · join 800+ traders
The top plays and unusual-volume catches our scanner flags, emailed to you. No account needed.
No spam. Unsubscribe anytime. Not investment advice.
Here is the latest on COAG from our scanner (live price and day move above). We have not detected an unusual-volume catalyst for COAG today, so it is trading in line with its recent range. The moment our scanner flags unusual activity, the reason will appear here.
Likely catalystHemab Therapeutics Holdings, Inc.: Q2 FY2026 results, three months to Jun 30, 2026, from an SEC filing. Read it →Latest filingSC 13GPassive 5%+ stake disclosedAug 14, 2026 · 37 days agoAcross every filing on file, supply equal to 27.1% of the tradeable float is in play - 27.1% has already been sold.
Recent priced share offering — a one-time sale that has already completed (not ongoing)
2,512,500 new shares
Sources: float & market cap via Polygon · short interest via FINRA · borrow & shortability via Alpaca · SSR from Reg SHO 201 · filings & dilution via SEC EDGAR · analysts via Nasdaq.
Auto-generated from public data for research and education. Not investment advice.
| Insider | Action | Shares | % of position | Owns after | Value | Date |
|---|---|---|---|---|---|---|
Ra Capital Management, L.P. Beneficial Owner (10%) | Bought (open market) | +62K 0.1% of company | added 0.8% | 7.81M | $1.5M at $24.98 | Jun 16, 26 |
Ra Capital Management, L.P. Beneficial Owner (10%) | Bought (open market) | +6K 0.01% of company | added <0.1% | 6.38M | $153K at $24.89 | Jun 15, 26 |
Ra Capital Management, L.P. Beneficial Owner (10%) | Bought (open market) | +996 | added <0.1% | 7.74M | $25K at $24.94 | May 20, 26 |
Ra Capital Management, L.P. Beneficial Owner (10%) | Bought (open market) | +4K | added <0.1% | 6.38M | $95K at $24.97 | May 19, 26 |
Ra Capital Management, L.P. Beneficial Owner (10%) | Bought (open market) | +6K 0.01% of company | added <0.1% | 7.74M | $159K at $24.90 | May 12, 26 |
Ra Capital Management, L.P. Beneficial Owner (10%) | Bought (open market) | +40K 0.09% of company | added 0.5% | 7.73M | $976K at $24.47 | May 11, 26 |
Ra Capital Management, L.P. Beneficial Owner (10%) | Bought (open market) | +1K | added <0.1% | 6.33M | $37K at $24.98 | May 8, 26 |
Ra Capital Management, L.P. Beneficial Owner (10%) | Bought (open market) | +10K 0.02% of company | added 0.2% | 6.32M | $241K at $24.34 | May 7, 26 |
Ra Capital Management, L.P. Director | Bought (open market) | +68K 0.1% of company | added 0.9% | 7.68M | $1.6M at $23.77 | May 6, 26 |
Ra Capital Management, L.P. Director | Bought (open market) | +97K 0.2% of company | added 1.6% | 6.25M | $2.4M at $24.59 | May 5, 26 |
Maraganore John Director | Acquired (grant/award) | +36K 0.08% of company | n/a | 36K | n/a | May 4, 26 |
Novo Holdings A/S Beneficial Owner (10%) | Acquired (grant/award) | +4.18M 8.9% of company | n/a | 4.18M | n/a | May 4, 26 |
Recent Form-4 filings via Nasdaq. Open-market buys are the signal worth watching. Grants and automatic (10b5-1) sells are routine. “% of position” is the share of that insider’s own holding the trade moved. Not investment advice.
Blend of news sentiment, today’s move, and community votes. Not investment advice.
News, unusual-volume alerts, AI-trader trades and community chatter - the whole story, newest first.
Comparable names in biological products, (no diagnostic substances), closest in size first.
Here is the latest on COAG from our scanner (live price and day move above). We have not detected an unusual-volume catalyst for COAG today, so it is trading in line with its recent range. The moment our scanner flags unusual activity, the reason will appear here.
COAG last traded at $41.19, down 0.07% on the day. The price and chart above update live during market hours (4 AM to 8 PM ET).
Hemab Therapeutics Holdings, Inc. Common Stock (COAG) is next expected to report earnings on Tuesday, November 10, 2026, about 51 days away. Earnings reports often cause large overnight gaps, so many traders manage risk around the date. The date can shift until the company officially confirms it.
The COAG Live Alerts panel on this page streams real-time unusual volume (RVOL), momentum, halt and 200-EMA alerts from our scanner the moment they fire. Our scanner has flagged COAG 58 times in the last 30 days.
COAG (Hemab Therapeutics Holdings, Inc. Common Stock) trades on XNAS, with a market cap of about $1.92B in the Biological Products, (No Diagnostic Substances) sector.
That depends on your strategy and risk. Day traders look for volume, volatility and a clear trend. Use the live chart, RVOL alerts and 200-EMA context on this page to judge COAG for yourself. This is not investment advice.
Live data from TheDesperateTrader scanner. Not investment advice.
$COAG discussion
Sign in to ask a question or join the discussion.